MedTrace Logo

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET

NCT04064840 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 784

Last updated 2026-05-15

No results posted yet for this study

Summary

The objectives of this study are to compare the efficacy of the dual trigger group vs the hCG trigger group on the live birth rate in women undergoing IVF and the efficacy of the agonist in LP group vs the placebo group on the live birth rate in women undergoing FET.

Conditions

  • Subfertility

Interventions

DRUG

IVF: Decapeptyl and hCG

When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.

DRUG

FET: Decapeptyl

On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.

DRUG

IVF: hCG and normal saline

When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.

DRUG

FET: Normal Saline

On the day of FET, normal saline will be injected subcutaneously.

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Ernest HY Ng, MD · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2024-09-01
Completion
2026-05-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064840 on ClinicalTrials.gov